Healthcare / Drug Manufacturers - Specialty & GenericKSE
$6340.00
-270.00 (-4.01%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 17%
FCF escenarios
weak_data · normalized FCF $-10.6B · quality 39.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
36/100
D
Piotroski
3/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$165.7B
P/E
N/A
•EV/EBITDA
25.2x
↑ROE
3.1%
↑Gross Margin
41.5%
↓Debt/Equity
0.61
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+5.6%
FCF CAGR
—
FCF margin
-3.1%
FCF / Net income
-2.38x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $191.79B · net income $2.52B · FCF $-5.99B
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $191.79B | $191.79B | $175.74B | $180.76B | $162.69B |
| Net Income | $2.52B | $2.52B | $-574.9M | $6.12B | $-164.6M |
| EBITDA | $8.47B | $8.47B | $3.94B | $13.24B | $10.13B |
| EPS | — | — | -22.00 | 226.00 | -6.00 |
| Gross Margin | 41.5% | 41.5% | 41.7% | 42.4% | 42.3% |
| Operating Margin | 2.2% | 2.2% | 0.1% | 3.8% | 4.9% |
| Net Margin | 1.3% | 1.3% | -0.3% | 3.4% | -0.1% |
| Balance Sheet | |||||
| Debt/Equity | 0.61 | 0.61 | 0.61 | 0.46 | 0.46 |
| Current Ratio | 2.20 | 2.20 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-5.99B | $-5.99B | $-13.56B | $-10.65B | $5.04B |
| Returns | |||||
| ROE | 3.1% | 3.1% | -0.7% | 7.2% | -0.2% |
| Valuation | |||||
| P/E | — | — | — | 17.96 | — |
| EV/EBITDA | 25.15 | 25.15 | 32.66 | 10.04 | 13.97 |
| P/B | 2.02 | 2.02 | 1.15 | 1.30 | 1.53 |
| Growth & Yield | |||||
| Revenue Growth | 9.1% | 9.1% | -2.8% | 11.1% | — |
| EPS Growth | — | — | -109.7% | 3866.7% | — |
| Dividend Yield | 0.5% | 0.5% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+95.6%
Start / end P/E
n/dx → n/dx
EPS bridge
-22.00 → n/d
Residual
+95.2%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.